Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa plasmodium falciparum merozoite surface protein-1

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Qian, Feng ^a,b   Reiter, Karine ^a   Zhang, Yanling ^a   Shimp, Richard L ^a   Nguyen, Vu ^a   Aebig, Joan A ^a   Rausch, Kelly M ^a   Zhu, Daming ^a   Lambert, Lynn ^a   Mullen, Gregory E D ^a,c   Martin, Laura B ^a,d   Long, Carole A ^a   Miller, Louis H ^a   Narum, David L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ALUMINUM HYDROXIDE; BACTERIAL PROTEIN; EXOPROTEIN A; MEROZOITE SURFACE PROTEIN 1; MONOMER; UNCLASSIFIED DRUG; CROSS LINKING REAGENT; IMMUNOGLOBULIN G; ISOPROTEIN; PROTOZOON ANTIBODY; PSEUDOMONAS EXOPROTEIN A PROTEIN, PSEUDOMONAS AERUGINOSA; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; COMPLEX FORMATION; CONJUGATE; CONJUGATION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PLASMODIUM FALCIPARUM; PROTEIN AGGREGATION; PROTEIN CROSS LINKING; PROTEIN PROCESSING; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GEL CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; LIGHT; METABOLISM; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; RADIATION SCATTERING; TITRIMETRY;

MUS; PLASMODIUM FALCIPARUM; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTIBODIES, PROTOZOAN; BACTERIAL PROTEINS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-LINKING REAGENTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; IMMUNOGLOBULIN G; LIGHT; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; MOLECULAR WEIGHT; PLASMODIUM FALCIPARUM; PROTEIN ISOFORMS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RECOMBINANT PROTEINS; SCATTERING, RADIATION; TITRIMETRY;

EID: 84861887093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036996     Document Type: Article

References (48)

1. Torano G, Toledo ME, Baly A, Fernandez-Santana V, Rodriguez F, et al. (2006) Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b in human adult volunteers. Clin Vaccine Immunol 13: 1052-1056.
2. Poolman J, Frasch C, Nurkka A, Kayhty H, Biemans R, et al. (2011) Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol 18: 327-336.
3. Broker M, Dull PM, Rappuoli R, Costantino P, (2009) Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 27: 5574-5580.
4. Thiem VD, Lin FY, Canh do G, Son NH, Anh DD, et al. (2011) The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 18: 730-735.
5. Wu Y, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, et al. (2006) Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci U S A 103: 18243-18248.
6. Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, et al. (2007) Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci U S A 104: 293-298.
7. Qian F, Wu Y, Muratova O, Zhou H, Dobrescu G, et al. (2007) Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine 25: 3923-3933.
8. Qian F, Aebig JA, Reiter K, Barnafo E, Zhang Y, et al. (2009) Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure. Microbes Infect 11: 408-412.
9. Stanisic DI, Martin LB, Liu XQ, Jackson D, Cooper J, et al. (2003) Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination. Infect Immun 71: 5700-5713.
10. Holder AA, Guevara Patino JA, Uthaipibull C, Syed SE, Ling IT, et al. (1999) Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia 41: 409-414.
11. Holder AA, (2009) The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 136: 1445-1456.
12. Egan A, Waterfall M, Pinder M, Holder A, Riley E, (1997) Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect Immun 65: 3024-3031.
13. Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, et al. (2001) Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun 69: 1536-1546.
14. Huaman MC, Martin LB, Malkin E, Narum DL, Miller LH, et al. (2008) Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J Immunol 180: 1451-1461.
15. Stowers AW, Chen LH, Zhang Y, Kennedy MC, Zou L, et al. (2002) A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci U S A 99: 339-344.
16. Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, et al. (2003) Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect Immun 71: 6766-6774.
17. Singh S, Miura K, Zhou H, Muratova O, Keegan B, et al. (2006) Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 74: 4573-4580.
18. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, et al. (2005) The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun 73: 287-297.
19. Malkin E, Long CA, Stowers AW, Zou L, Singh S, et al. (2007) Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin Trials 2: e12.
20. Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, et al. (2010) Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One 5: e8787.
21. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, et al. (2009) Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 4: e4708.
22. Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, et al. (2009) Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine 28: 452-462.
23. Faber BW, Remarque EJ, Morgan WD, Kocken CH, Holder AA, et al. (2007) Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infect Immun 75: 5947-5955.
24. Xue X, Ding F, Zhang Q, Pan X, Qu L, et al. (2010) Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant. Vaccine 28: 3152-3158.
25. Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM, (2004) The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol Lett 92: 259-268.
26. Ogun SA, Dumon-Seignovert L, Marchand JB, Holder AA, Hill F, (2008) The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria. Infect Immun 76: 3817-3823.
27. Weiss R, Gabler M, Jacobs T, Gilberger TW, Thalhamer J, et al. (2010) Differential effects of C3d on the immunogenicity of gene gun vaccines encoding Plasmodium falciparum and Plasmodium berghei MSP1(42). Vaccine 28: 4515-4522.
28. Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, et al. (2010) Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. Vaccine 28: 2818-2826.
29. Shimp RL Jr, Martin LB, Zhang Y, Henderson BS, Duggan P, et al. (2006) Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag. Protein Expr Purif 50: 58-67.
30. Brady CP, Shimp RL, Miles AP, Whitmore M, Stowers AW, (2001) High-level production and purification of P30P2MSP1(19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris. Protein Expr Purif 23: 468-475.
31. Shuler KR, Dunham RG, Kanda P, (1992) A simplified method for determination of peptide-protein molar ratios using amino acid analysis. J Immunol Methods 156: 137-149.
32. Mullen GE, Giersing BK, Ajose-Popoola O, Davis HL, Kothe C, et al. (2006) Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24: 2497-2505.
33. Aebig JA, Mullen GE, Dobrescu G, Rausch K, Lambert L, et al. (2007) Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods 323: 139-146.
34. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, et al. (2008) Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26: 193-200.
35. Qian F, Rausch KM, Muratova O, Zhou H, Song G, et al. (2008) Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 26: 2521-2527.
36. Saul A, Lawrence G, Allworth A, Elliott S, Anderson K, et al. (2005) A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23: 3076-3083.
37. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, et al. (2005) Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73: 3677-3685.
38. Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, et al. (2009) A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27: 3090-3098.
39. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM, (2010) Virus-like particles in vaccine development. Expert Rev Vaccines 9: 1149-1176.
40. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359: 2521-2532.
41. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, et al. (2008) Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 359: 2533-2544.
42. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al. (2011) First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. N Engl J Med 365: 1863-1875.
43. Saul A, (2008) Efficacy model for mosquito stage transmission blocking vaccines for malaria. Parasitology 135: 1497-1506.
44. Near KA, Stowers AW, Jankovic D, Kaslow DC, (2002) Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model. Infect Immun 70: 692-701.
45. Hirunpetcharat C, Wipasa J, Sakkhachornphop S, Nitkumhan T, Zheng YZ, et al. (2003) CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine 21: 2923-2932.
46. Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, et al. (2004) CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 72: 949-957.
47. Coban C, Ishii KJ, Stowers AW, Keister DB, Klinman DM, et al. (2004) Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Infect Immun 72: 584-588.
48. Jeamwattanalert P, Mahakunkijcharoen Y, Kittigul L, Mahannop P, Pichyangkul S, et al. (2007) Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice. Clin Vaccine Immunol 14: 342-347.